This site is intended for healthcare professionals

Early use of anakinra reduces risk of mortality for patients with COVID-19 pneumonia, reduces ICU admission and increases likelihood of full recovery.- Swedish Orphan Biovitrum

Read time: 2 mins
Last updated:21st May 2021
Published:22nd May 2021
Swedish Orphan Biovitrum AB (publ) (Sobi) and the Hellenic Institute for the Study of Sepsis today announced positive day 28 full results from the investigator-sponsored SAVE-MORE study.
Condition: Coronavirus/COVID-19 Infection
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest